Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia
Psychological Medicine · 2026 · 56
DOI: 10.1017/s0033291726104024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Psychological Medicine, online erschienen am 28.05.2026. Verfasst von Chang Lu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China. Hauptthemen laut MEDLINE: Schizophrenia, Antipsychotic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.
Abstract (Originalsprache)
Background
This real-world study aimed to characterize patients with schizophrenia who achieve sustained good functional outcomes after antipsychotic discontinuation and to develop the Functional Remission in Schizophrenia after Antipsychotic Discontinuation (FURSAD) predictive model.
Methods
We retrospectively identified individuals aged 18–65 years with schizophrenia (ICD-10) from the Shanghai Mental Health Center discharge database. Patients who discontinued antipsychotics for ≥1 year were classified as functional remission (FR) or functional non-remission (FNR) based on functioning assessments. Sociodemographic, clinical, and treatment-related data were extracted blindly from hospital records and structured interviews.
Results
Among 4,166 discharged patients screened, 180 met the inclusion criteria (FR: 116; FNR: 64). Six independent predictors were identified: total disease course, Clinical Global Impression-Severity (CGI-S) score, Positive and Negative Syndrome Scale (PANSS) emotional distress subscale score, use of first-generation antipsychotics, discontinuation due to treatment benefits, and discontinuation due to lack of insight. The logistic regression model showed strong predictive performance (AUC = 0.867, 95% CI 0.813–0.921), with 82.8% sensitivity and 81.9% specificity. Internal validation was performed via 10-fold cross-validation.
Conclusion
Discontinuation motives and illness trajectory are relevant in predicting long-term functional outcomes. A limitation is that a substantial number of patients could not be recontacted or declined participation, which may introduce selection bias. The FURSAD nomogram may help clinicians estimate the probability of FR 4.5 years post-antipsychotic discontinuation in patients previously on antipsychotics for ≥3 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Clinical Center for Psychotic Disorders, National Center for Mental Disorders, Shanghai, China.
- Department of Psychiatry, Huashan Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Chang Lu, Dengtang Liu
Förderung
- National Natural Science Foundation of China
- Science and Technology Commission of Shanghai Municipality
Zitieren
APA
Lu, C., Dong, Y., Zhai, Z., Gao, T., Luo, M., Chang, D., Chen, J., Xue, J., Zhao, Y., Xiang, Q., Li, X., Ma, X., Wei, Z., Feng, T., & Liu, D. (2026). Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia. Psychological Medicine, 56. https://doi.org/10.1017/s0033291726104024
Vancouver
Lu C, Dong Y, Zhai Z, Gao T, Luo M, Chang D, et al. Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia. Psychological Medicine. 2026;56. doi:10.1017/s0033291726104024
BibTeX
@article{Lu2026,
author = {Lu, Chang and Dong, Yuke and Zhai, Zhaolin and Gao, Tianhao and Luo, Mengyi and Chang, Di and Chen, Jing and Xue, Jingxin and Zhao, Yuqing and Xiang, Qiong and Li, Xuan and Ma, Xiangyi and Wei, Zheyi and Feng, Tienan and Liu, Dengtang},
title = {Predicting functional remission after antipsychotic discontinuation: a real-world study in schizophrenia},
journal = {Psychological Medicine},
year = {2026},
volume = {56},
doi = {10.1017/s0033291726104024}
}
EUVIMED